

## RECOMBINANT VACCINE AGAINST JAPANESE ENCEPHALITIS VIRUS (JEV) INFECTION AND A METHOD THEREOF

### Field of the invention

5 The present invention relates to a method of preparing a novel recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection. Also, it relates to a method of immunization and to the vaccine *per se*.

### Background and prior art references of the invention

Japanese encephalitis virus (JEV) is a member of the *flaviviridae* family of animal viruses that consists of several viruses of immense medical significance such as those causing dengue and yellow fever. JEV, transmitted to human beings by mosquitoes, is responsible for an acute infection of the central nervous system resulting in encephalitis. The virus is active over a vast geographic area covering India, China, Japan and virtually all of the South-East Asia. Approximately 3 billion people live in JEV endemic area and up to 50,000 cases of JEV infection are reported every year, of which, about 10,000 cases result in fatality and a high proportion of survivors end up having serious neurological and psychiatric sequel (45). A mouse brain-grown, formalin-inactivated JEV vaccine is available internationally. However, this vaccine has limitations in terms of its high cost of production, lack of long-term immunity and risk of allergic reaction due to the presence of the murine encephalogenic basic proteins or gelatin stabilizer (1, 33, 38, 39). There is, thus, an urgent need to develop an improved vaccine against JEV and several potential vaccines are currently being investigated in various laboratories (16).

JEV contains a single-stranded, plus-sense RNA genome of ~11 Kb. It consists of a single open reading frame that codes for a large polyprotein of 3432 amino acids which is co- and post-translationally cleaved into three structural (capsid, C; pre-membrane, prM; and envelope, E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (5, 44). In flaviviruses, E protein is involved in a number of important functions related to virus infection such as receptor binding and membrane fusion (26). Antibodies to the E protein were shown to neutralize virus activity *in vitro* as well as *in vivo* since passive administration of monoclonal antibodies to the E protein protected mice with JEV infection (17). Furthermore, sub-viral particles consisting of only the prM and the E proteins were highly effective in generating protective immune response in mice against JEV (18, 25). Chen *et al.* (7) examined the potential of

various JEV structural and non-structural proteins for vaccine development. They concluded that the E protein was the single most important protein capable of inducing protective immunity against JEV. Accordingly, several plasmid vectors have been described synthesizing different forms of JEV E protein with or without prM protein 5 and these provided protection of varying degree in mice against Japanese encephalitis (2, 6, 15, 20).

In recent years, adenoviruses have shown great promise as vectors for recombinant vaccine development (3, 4, 8, 13, 35, 41, 42, 49). Besides being safe, these viruses have been shown to induce effective humoral and cellular immune responses in 10 experimental animals when delivered orally, intra-muscular (IM), intra-peritoneal or intra-nasal (3, 21, 24, 40, 41, 50). In the present invention, we constructed RAdEa expressing the prM and the full length JEV E protein since it is known to induce neutralizing immune response. However, adenovirus recombinant (RAdEa) synthesizing the full-length protein (Ea) did not grow well. Besides it induced poor 15 immune response and very little JEV neutralizing antibodies. The full-length E protein is membrane anchored and removing the anchor signal from it is likely to make it soluble and perhaps more immunogenic.

On this premise, we truncated the Ea protein to remove 102-amino acid hydrophobic sequence from the C-terminus of the protein to generate a 398-amino acid Es protein. 20 Recombinant adenovirus RAdEs synthesizing JEV prM and Es was found to grow very well in cultured cells and synthesize JEV E protein that was secreted into the medium. So, the removal of 102-amino acid hydrophobic sequence from the C-terminus of the protein played a critical role in smooth culturing of the recombinant. Even the inventors were pleasantly surprised with this effect.

25 Further, this recombinant adenovirus, synthesizing a novel form of JEV E protein that was secretory as opposed to the anchored protein in the normal course, was highly immunogenic in mice. RAdEs induced high titers of JEV neutralizing antibodies and protected the immunized mice against lethal JEV challenge demonstrating its potential use as a vaccine against JEV infection. The highly immunogenic effect of the 30 recombinant helped achieve the desired results, which were long awaited by the scientific community.

The infection caused by JEV is fatal in nature and absence of long-term immunity had added to the problem. The allergic reactions to the known vaccine had further

compounded the problem. However, administration of the vaccine of instant invention is been found to be absolutely safe and free from adverse effects.

### **Objects of the invention**

The main object of the present invention is to develop a recombinant adenovirus

5 (RAdEs) vaccine against JEV infection.

Another main object of the present invention is to develop an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection.

Yet another object of the present invention is to develop a plasmid pAdEs of SEQ ID No. 1.

10 Still another object of the present invention is to develop a method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection.

### **Summary of the invention**

The present invention relates to development of a novel recombinant adenovirus (RAdEs) vaccine against Japanese encephalitis virus (JEV) infection.

### **Detailed description of the invention**

Accordingly, the present invention relates to a novel recombinant adenovirus (RAdEs) vaccine against JEV infection; an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection; also, a plasmid pAdEs of SEQ ID No. 1; 20 and lastly, a method of preparing the recombinant adenovirus (RAdEs) vaccine.

In the main embodiment of the present invention, it relates to a method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection, wherein the said vaccine produces secretory envelop protein of JEV, said method comprising steps of:

- 25           • digesting plasmid pMEs with restriction enzymes *Kpn* I and *Bam* HI to obtain cDNA encoding JEV proteins prM and Es,
- ligating the cDNA to adenovirus shuttle plasmid pShuttle digested with restriction enzymes *Kpn* I and *Hind* III at the *Kpn* I end,
- filling nucleotides at the free *Bam* HI and *Hind* III ends with T4 DNA polymerase to create blunt ends,
- ligating the blunt ends together to yield shuttle plasmid pSEs with JEV cDNA encoding the proteins prM and Es,

- digesting the shuttle plasmid pSEs with restriction enzymes I-Ceu I and PI-Sce I to obtain expression cassette containing the JEV cDNA together with the CMV promoter/enhancer and BGH polyadenylation signal,
- 5 • ligating the digested shuttle plasmid with I-Ceu I and PI-Sce I digested adenovirus plasmid pAdeno-X to generate plasmid pAdEs containing the Es expression cassette,
- digesting the plasmid pAdEs with Pac I,
- transfecting the monolayers of HEK 293 cells with digested plasmid 10 pAdEs for about one week, and
- obtaining the recombinant virus RAdEs vaccine.

In another embodiment of the present invention, the transfection is at about 37°C temperature.

In yet another embodiment of the present invention, the secretory proteins are under the 15 control of human CMV IE promoter/enhancer.

In another main embodiment of the present invention, the invention relates to a recombinant adenovirus (RAdEs) vaccine.

In yet another embodiment of the present invention, the vaccine produces secretory envelop protein (Es) of JEV.

20 In still another embodiment of the present invention, the vaccine protects against Japanese encephalitis virus (JEV) infection.

In still another embodiment of the present invention, the vaccine is effective by intra-muscular route of administration.

In another main embodiment of the present invention, the invention relates to a plasmid 25 pAdEs of SEQ ID No. 1.

In another main embodiment of the present invention, the invention relates to an effective and superior method of immunizing a subject in need thereof, to Japanese encephalitis virus (JEV) infection, said method comprising the step of administering a pharmaceutically effective amount of recombinant virus RAdEs vaccine optionally 30 along with additive(s) to the subject intra-muscularly.

In yet another embodiment of the present invention, the method shows 100% efficacy.

In still another embodiment of the present invention, the method helps protect subject against Japanese encephalitis.

In still another embodiment of the present invention, the subject is animal.

In still another embodiment of the present invention, the subject is a human being.

In still another embodiment of the present invention, the immunization activates both humoral and cell-mediated immune responses.

5 In still another embodiment of the present invention, the humoral response to the vaccine is antibody IgG1 type.

In still another embodiment of the present invention, the method leads to high amount of IFN-gamma secretion.

10 In still another embodiment of the present invention, the immunization leads to IL-5 secretion at moderate levels.

In still another embodiment of the present invention, increased amounts of RAdEs lead to higher immune response.

In still another embodiment of the present invention, the method is more effective than the commercially available vaccine.

15 Replication-defective recombinant adenoviruses (RAds) were constructed that synthesized the pre-Membrane (prM) and envelope (E) proteins of Japanese encephalitis virus (JEV). Recombinant virus RAdEa synthesized Ea, the membrane-anchored form of the E protein, and RAdEs synthesized Es, the secretory E protein. RAdEa replicated poorly in human embryonic kidney (HEK) 293A cells and 88-folds 20 lower titers of the virus were obtained compared to RAdEs. RAdEa also synthesized lower amounts of E protein in HEK 293A cells as judged by radioimmunoprecipitation and immunofluorescence studies.

Mice were immunized intra-muscular (IM) and orally with RAds. Oral route of virus delivery induced low titers of anti-JEV antibodies that had only little JEV neutralizing 25 activity. IM immunizations with both RAdEa and RAdEs resulted in high titers of anti-JEV antibodies. Interestingly, RAdEa induced very low titers of JEV neutralizing antibodies whereas RAdEs inoculation resulted in high titers of JEV neutralizing antibodies. Splenocytes from mice immunized IM with RAds secreted large amounts of interferon- $\gamma$  and moderate amounts of interleukin-5. These splenocytes also showed 30 cytotoxic activity against JEV-infected cells. Mice immunized IM with RAdEs showed complete protection against the lethal dose of JEV given intra-cerebral.

**Brief description of the accompanying drawings:**

**Fig. 1** shows Growth of RAdS in HEK 293A cells. Monolayers of HEK 293A cells in 35-mm tissue culture dishes were infected with RAdS at a multiplicity of infection (MOI) of 1 and incubated at 37 °C in 3 ml culture medium. At 6 hr interval the cell monolayers were lysed in the culture medium by three cycles of freeze-thawing. The cell lysate was centrifuged to remove the debris and the supernatant assayed for adenovirus titers on HEK 293A cells. Shown in the figure are virus titers at various time points.

**Fig. 2** shows Synthesis of JEV proteins in HEK 293A cells infected with RAdS. HEK 293A cells were infected with JEV or RAdS at a MOI of 1. Cells were labelled 24 hr later by growth in medium containing  $^{35}$ S-methionine and  $^{35}$ S-cystine. After labeling, culture supernatant (CS) and cells were harvested separately. Cells were washed with PBS before the cell lysate (CL) was made. CLs and CSs were used for immunoprecipitation of JEV proteins with mouse anti-JEV serum. The proteins were separated on a 12% SDS-polyacrylamide gel and autoradiographed. Lanes containing proteins precipitated from JEV-, RAdEa- or RAdEs-infected or uninfected cells have been identified. Position of JEV proteins has been indicated at the left. Ea, Es and prM proteins synthesized by RAdS have been indicated. The values on the right are molecular size markers in kDa.

**Fig. 3** shows Immunofluorescent staining of virus-infected cells. HEK 293A cells were infected with RAdS or JEV at a MOI of 1. The cells were fixed and permeabilized 24 hr later and stained with mouse anti-JEV serum followed by FITC-conjugated goat anti-mouse-IgG. They were then observed under a microscope using ultra-violet light. Panel A, RAdEa-infected cells; panel B, RAdEs-infected cells; panel C, JEV-infected cells and panel D, uninfected cells.

**Fig. 4** shows Antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAdS) and the routes of inoculation have been indicated below the figure. \*indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer (pH 8.9). The primary immunization was followed by booster doses that were given 21 and 36 days later. Mice were bled at day 20, 28 and 44 post-immunization and sera stored at -70 °C. Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point anti-JEV antibody titers by ELISA.

Shown above are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent titers on day 20, the gray bars represent titers on day 28 and black bars show titers on day 44 post-immunization.

**Fig. 5** shows Isotype analysis of anti-JEV antibody produced by immunized mice.

5 BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAd) and the routes of inoculation have been indicated below the figure. The primary immunization was followed by booster doses given 21 and 36 days later. Mice sera obtained on day 44 post-immunization were assayed for the end-point ELISA titers of anti-JEV IgG1 and  
10 IgG2a antibodies. Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point titers. The ELISA titer was recorded as zero if the 1:25 dilution of sample was negative in ELISA. Shown in the figure are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent IgG1 titers and the gray bars represent IgG2a titers. The inverted triangle indicates zero mean  
15 titer.

**Fig. 6** shows JEV neutralizing antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation. The dosages of the immunogens and the route of inoculation have been indicated at the top of the figure. The primary immunization was followed by booster doses given 21 and  
20 36 days later. \*indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer. Mice were bled on day 44 post-immunization and sera stored at -70 °C. Serial two-fold dilutions of sera (starting at 1:10) were assayed for end-point JEV neutralization titers by plaque reduction neutralization assays. Shown in the figure are mean JEV neutralization titers of serum samples from immunized mice.

25 **Fig. 7** shows Cytokine production by splenocytes from immunized mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation as indicated at the top of the figure. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were  
30 cultured in presence of JEV. Culture supernatants were collected each day and stored at -70 °C. These were then assayed for IFN- $\gamma$ , IL-4 and IL-5. Shown in the figure are the levels of IFN- $\gamma$  and IL-5 in splenocyte cultures on various days after incubation with JEV. The days are numbered at the bottom of the panel.

Fig. 8 shows CTL activity in immunized mice. BALB/c mice were immunized with RAdEa or RAdEs by IM route of inoculation. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were cultured in presence of JEV for the generation of effector cells. Shown in the figure is the CTL activity of splenocytes at various ratios of effector cells to target cells (E : T) which are indicated at the bottom of the panels.

Fig. 9 shows Mice survival after challenge. Groups of 6-8 BALB/c mice were immunized with various dosages of RAdEa and RAdEs through IM or oral route. These mice received two booster doses of the immunogen on day 22 and 36 post-immunization. Mice were challenged on day 44 post-immunization with 100 LD<sub>50</sub> (50%-lethal dose) of JEV given intra-cerebrally. Mice were observed for mortality for the next three weeks. Shown above is the percentage of surviving mice at a given time point. Immunogen dose and route of inoculation have been indicated. \*indicates oral delivery of RAdEs along with the bicarbonate buffer.

The invention is further elaborated with the help of experimental data, as presented below in the form of examples. However, the examples should not be construed to limit the scope of the invention

#### Example – 1

JEV and cells: The GP78 strain of JEV was used in these studies (44). The virus was grown in neonatal mouse brain. The brain from infected mice was homogenized as a 10% suspension in Eagle's minimal essential medium (EMEM). The suspension was centrifuged and filtered through 0.22 µm sterile filters. The virus was stored at -70 °C in aliquots. Virus titration was carried out by plaque assay on porcine stable kidney (PS) monolayers as described previously (43). Adenovirus was grown in human embryonic kidney (HEK) 293A cells (Quantum Biotechnologies Inc.) cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS).

#### Example – 2

Construction of recombinant adenoviruses: Recombinant adenoviruses were constructed using the Adeno-X expression system (BD Biosciences) that utilized a ligation-based strategy for producing recombinant virus. Using this system a mammalian expression cassette containing the cDNA encoding JEV E protein was

incorporated into a replication incompetent ( E1/ E3) human adenovirus type 5 (Ad5) genome. Two recombinant adenoviruses (RAds) were made; RAdEa, synthesizing JEV prM and the membrane-anchored E protein, and RAdEs, synthesizing prM and the secretory E protein. Plasmids pMEA and pMEs that contained the cDNAs encoding 5 JEV prM and the membrane-anchored (Ea) or secretory E protein (Es), respectively have been described previously (15). Plasmid pMEA was modified by site-directed mutagenesis to contain an *Afl* II restriction site down-stream of the 3'-end of the JEV cDNA past the *Bam* HI site. The JEV cDNA encoding the prM and Ea proteins was excised from the mutated pMEA as a *Kpn* I - *Afl* II fragment and cloned at these sites in 10 the adenovirus shuttle plasmid pShuttle (BD Biosciences) under the control of human cytomegalovirus (CMV) immediate early (IE) promoter/enhancer to yield plasmid pSEa. The shuttle plasmid pSEa contained the bovine growth hormone (BGH) polyadenylation signal downstream of the cloned JEV cDNA. The cDNA encoding prM and Es sequence was obtained by digesting pMEs with *Kpn* I and *Bam* HI. This 15 cDNA fragment was ligated to the adenovirus shuttle plasmid, pShuttle, digested with *Kpn* I and *Hind* III at the *Kpn* I end. The free *Bam* HI and *Hind* III ends were nucleotide filled with T4 DNA polymerase and the blunt ends so created were ligated together to yield plasmid pSEs where JEV cDNA encoding prM and Es was under the control of human CMV IE promoter/enhancer. The shuttle plasmid pSEs contained the 20 BGH polyadenylation signal downstream of the cloned cDNA. The junctions of the shuttle plasmid and the cDNA insert were sequenced to confirm the presence of the cDNA in correct frame. The plasmids pSEa and pSEs were digested with *I-Ceu* I and *P1-Sce* I to obtain the expression cassettes containing the JEV cDNA together with CMV promoter/enhancer and BGH polyadenylation signal. These were then ligated 25 with *I-Ceu* I and *P1-Sce* I digested adenovirus plasmid pAdeno-X (BD Biosciences) to generate plasmids pAdEa and pAdEs containing the Ea and Es expression cassettes, respectively. Monolayers of HEK 293A cells were transfected with *Pac* I digested pAdEa and pAdEs using Effectene (Qiagen) and incubated for a week at 37 °C. By this time, RAd plaques had begun to show. The cell monolayers were harvested in culture 30 supernatant, frozen-thawed thrice and centrifuged to obtain the released crude recombinant virus that was amplified once in HEK 293A cells and subjected to 2 rounds of plaque purification to obtain recombinant viruses RAdEa and RAdEs.

**Example – 3**

**Radioimmunoprecipitation:** Synthesis of JEV proteins by RAdEa and RAdEs was studied by infection of HEK 293A cells followed by radiolabelling and immunoprecipitation. Briefly, monolayers of HEK 293A cells were infected with virus at a multiplicity of infection (MOI) of 1 and incubated at 37 °C. After 24 hr, the cell monolayer was radiolabelled by growing in presence of 100 µCi of Easytag™ EXpre<sup>35</sup>S<sup>35</sup>S protein labeling mix (NEN) for 4 hr. The culture supernatant was harvested and stored at -70 °C. The monolayers were harvested in 500 µl of radioimmunoprecipitation assay buffer (10 mM Tris-HCl pH 8.0, 140 mM NaCl, 5 mM Iodoacetamide, 0.5% Triton X-100, 1% Sodium dodecyl sulphate (SDS), 1% Sodium deoxycholate, 2 mM Phenylmethylsulfonyl fluoride). Immunoprecipitation was carried out using mouse anti-JEV serum (ATCC) and Protein A Sepharose beads (Amersham). Immunoprecipitated proteins were electrophoresed on a 12% SDS-polyacrylamide gel that was dried before exposing to X-ray film for autoradiography.

**Example – 4**

**Immunofluorescent staining:** Monolayers of HEK 293A cells were infected with RAdEa, RAdEs or JEV at a MOI of 1. The cells were fixed the next day with 2% Paraformaldehyde and permeabilized with 0.1% Triton-X 100. These cells were then stained by incubation with mouse anti-JEV serum (ATCC) followed by anti-mouse IgG-FITC conjugate (Dako) and observed under a microscope using ultra-violet light.

**Example – 5**

**Mice immunization and challenge experiments:** All immunizations were carried out on 4-5-week-old inbred BALB/c mice. Each immunization group consisted of 6-8 mice. For IM immunizations, mice were injected in the hind legs with different amounts of RAdS diluted in 100 µl phosphate-buffered saline (PBS) using a 30G needle. Another group of mice was immunized with the mouse brain-derived, formalin-inactivated JEV vaccine manufactured by the Central Research Institute, Kasauli (India). Each mouse was given an IM injection of 100 µl of the vaccine that was 1/10<sup>th</sup> of the recommended adult human dose. For oral immunizations, water was withdrawn from the mice cages for 6-8 hr and then 200-400 µl virus diluted in PBS or 100 mM Sodium bicarbonate buffer (ph 8.9) was administered per oral using a mouse-feeding needle that had a small balloon at the point of the delivery. Two booster doses, given 3 and 5 weeks after the primary immunization, contained the same amount of

immunogen as the primary dose. At 44 days post-immunization, mice were challenged with intra-cerebral inoculation of the lethal dose of JEV. These mice were observed for mortality for the next 3 weeks.

**Example – 6**

5   **Antibody assays:** Titers of anti-JEV antibodies were assayed using an enzyme-linked immunosorbent assay (ELISA). An ELISA plate was coated with C6/36 cell-grown JEV overnight at 4 °C in 0.2 M Sodium carbonate buffer, pH 9.6 (36). The plate was washed with PBS containing 0.1% Tween-20 (PBS-T) thrice and the wells were blocked with 1% Lactogen in PBS-T at 37 °C for 2 hr. The plate was again washed  
10 with PBS-T thrice and incubated with 100 µl diluted mice sera per well at 37 °C for 1 hr. Serial two-fold dilutions of sera were assayed starting at a dilution of 1:25. The plate was then washed thrice with PBS-T and 100-µl anti-mouse antibody conjugated to horse radish peroxidase (HRP) (Dako), diluted 1:2000, was added per well, followed by incubation at 37 °C for 1 hr. The antibody-conjugate was removed by washing the  
15 plate thrice with PBS-T. The plate was then incubated in dark with 100 µl per well of the substrate o-Phenylenediamine dihydrochloride (0.5 mg/ml) prepared in citrate buffer (1% Citric acid and 1.46% Disodium hydrogen phosphate) at room temperature for 10 min. The reaction was stopped by adding 50 µl of 5 N Sulfuric acid. The absorbance was read at 492 nm in an ELISA plate reader (Spectramax). The reciprocal  
20 of the highest serum dilution giving an optical density at least twice that given by the reagent blanks was taken as the ELISA end-point.

The antibody isotyping ELISAs were carried out in a similar fashion, except that in place of anti-mouse IgG-HRP conjugate, anti-mouse IgG1-HRP or the IgG2a-HRP conjugate (Pharmingen) was added. This was followed by the incubation with the  
25 substrate and color development as above.

**Example – 7**

**Plaque reduction neutralization assay:** Two fold serial dilutions of sera from the immunized mice (starting from 1:10) were prepared in EMEM containing 5% FCS and antibiotics. Diluted sera were incubated at 56 °C for 30 min to inactivate the complement. The serum sample (100 µl) was then mixed with equal volume of JEV culture supernatant containing 100 plaque-forming units (PFU) of the virus. The virus-antibody mixture was incubated at 37 °C for 1 hr before adding to a 35-mm dish containing ~70% confluent monolayer of PS cells. The plaque assay was carried out as

described. (43). Percent neutralization was calculated by counting the number of plaques in the presence and the absence of the mouse serum. All assays were done in duplicates. Reciprocal of the highest serum dilution giving 50% neutralization was taken as the JEV neutralization titer.

5      **Example – 8**

**Cytokine ELISA:** Spleen cell suspensions were prepared in RPMI 1640 supplemented with 10% FCS and  $6 \times 10^7$  splenocytes were incubated with  $3 \times 10^7$  PFU of JEV or *E. coli*-synthesized JEV E protein (10 µg/ml) in a 35-mm dish at 37 °C. Aliquots of culture supernatant were removed every day for the next 4 days and stored at –70 °C.  
10 Interleukin (IL)-4, IL-5 and interferon (IFN)- $\gamma$  were assayed using BD OptELIA kits (BD Biosciences) and as per the assay protocols.

**Example – 9**

**Cytotoxic T lymphocyte (CTL) assay:** Standard  $^{51}\text{Cr}$ -release method as described previously (15) was used for the CTL assays with some modifications. Briefly, for preparation of the responder cells,  $3 \times 10^7$  splenocytes were incubated for 4 days with  $3 \times 10^7$  PFU of JEV in a 35-mm dish in RPMI 1640 medium supplemented with antibiotics, 0.5 mM  $\beta$ -Mercaptoethanol, 0.32 mg/ml L-Glutamine, 0.1 mg/ml non-essential amino acids, 0.12 mg/ml Sodium pyruvate and 5% FCS at 37 °C. The cells thus generated were referred to as the effector cells. Virus-infected target cells were prepared by infecting P388D1 cells with JEV for 48 hr at a MOI of 1 followed by incubation with 100 µCi of  $\text{Na}_2^{51}\text{CrO}_4$  (NEN) and subsequent washings to remove free  $^{51}\text{Cr}$ .  
15  
20

For carrying out the CTL assay, various numbers of effector cells were incubated at 37°C for 6 hr with  $2 \times 10^4$   $^{51}\text{Cr}$ -labelled virus-infected cells by briefly centrifuging them at 100 g for 4 min in a 96-well round bottom plate. At the end of the incubation period, 100 µl of cell-free supernatant was removed and the  $^{51}\text{Cr}$  release was counted using a gamma counter (LKB). Triplicate estimations were done in all the assays and the percentage lysis was calculated using the following formula. Percent lysis = [(cpm released in the presence of effector cells – cpm released due to spontaneous leakage)/(total cpm released by 0.2% Triton X-100 lysis – cpm released due to spontaneous leakage)] x 100.  
25  
30

**Statistical analysis:** The statistical significance of different findings between mouse groups was determined by Student's *t* test.  $P \leq 0.05$  was considered to be significant.

**Example - 10**

**Replication of RAds and synthesis of JEV proteins:** The JEV E protein is 500 amino acids long membrane-anchored protein. We have earlier shown that deletion of the C-terminal 102 amino acids of JEV E protein leads to efficient secretion of the truncated protein into the cell surroundings (15). We had also shown that quality of immune responses in mice induced by the secretory E protein were different from those induced by the membrane-anchored E protein (15). Besides, vaccinia recombinants expressing the secretory E protein of Japanese encephalitis or Dengue viruses devoid of the membrane anchor sequence were found to be highly immunogenic in mice (14, 27, 37).

We, therefore, constructed two recombinants, RAdEa synthesizing prM and Ea (full-length membrane-anchored JEV E protein) and RAdEs synthesizing prM and Es (398 amino acid secretory E protein). The JEV prM was included in our constructs as its co-synthesis was necessary for correct processing and folding of the E protein (18, 25). The presence of appropriate JEV cDNA in genomes of RAds was established by polymerase chain reaction using JEV genome sequence-specific oligonucleotide primers.

Replication of RAds was studied in HEK 293A cells infected at a MOI of 1. Figure 1 shows that a major burst in viral titers was observed both for RAdEa and RAdEs between 18 and 24 hr post-infection (PI) after which there was only a marginal increase in titers. RAdEs titer was ~40-fold higher than that of RAdEa at 24 hr PI. Following the virus replication, the cytopathic effects were first visible at 30 hr PI for both RAdEa and RAdEs. The cytopathic effects had become highly pronounced by 42 hr PI when almost 80% cells had come off the surface of the tissue culture plates. At this time point titer of RAdEs was  $1.2 \times 10^7$  PFU/ml, which was 88-times higher than that of RAdEa. These results showed that compared to RAdEs, RAdEa replicated poorly in HEK 293A cells. We studied four independent isolates of RAdEa and found all them to be slow growers.

The synthesis of JEV proteins by RAds was studied in HEK 293A cells that were infected with different viruses followed by radiolabelling and immunoprecipitation of JEV proteins using mouse anti-JEV serum. Figure 2 shows that RAdEa-infected cell lysate had 2 proteins of apparent molecular masses of 51 and 23 kDa that corresponded with JEV E and prM proteins. None of these proteins were detectable in the culture supernatant of the infected cells. The RAdEs-infected cell lysate showed the synthesis

of Es and prM proteins of apparent molecular masses of 45 and 23 kDa, respectively. The culture supernatant from the RAdEs-infected cells had a significant amount of Es, indicating that the E protein synthesized by RAdEs was secretory.

Use of increased amounts of anti-JEV antibody and Protein A Sepharose in immunoprecipitations did not result in precipitation of enhanced amounts of E protein indicating that the amounts of these reagents used were not limiting. Scanning of the autoradiograph with optically-enhanced densitometer using 'Diversity One' software (version 1.6, PDI, New York) followed by calculations based on the volumes of the lysate or the supernatant loaded on the gel, suggested that the secretory E protein present in the culture supernatant constituted about 76% of the total E protein synthesized by RAdEs-infected cells. Furthermore, levels of total Es protein synthesis were around 20-fold higher than the levels of Ea protein. Immunofluorescent staining of RAdEa- and RAdEs-infected HEK 293A cells further confirmed that levels of Ea protein were significantly lower than that of the Es protein (Figure 3). The lower levels of Ea synthesis may be related to the poor growth of RAdEa in HEK 293A cells.

We found that RAdEa synthesizing the membrane-anchored E protein grew slowly and achieved 88-fold lower titers in HEK 293A cells when compared with RAdEs synthesizing the secretory E protein. Infection of HEK 293A cells with the recombinants followed by radioimmunoprecipitation of JEV proteins showed that RAdEa synthesized lower amounts of JEV E protein. This was corroborated by the low levels of immunofluorescence on RAdEa-infected HEK 293A cells when compared with RAdEs-infected cells. HEK 293A cells support replication of E1-deleted RAdS reported in this work as these cells contain Ad5 E1 transcription unit permanently integrated in them. In other mammalian cells these RAdS are unable to replicate for the want of the E1 sequences. However, expression of the foreign gene does take place, which is under the independent control of the CMV IE promoter. We have studied expression of JEV E protein by RAdS in PS cells by immunofluorescence and radioimmunoprecipitation. No significant differences were found in the levels of E protein synthesis in PS cells infected with RAdEa or RAdEs at a MOI of 1.

The adenovirus vector used in our studies had deletions in both the E1 and E3 transcription units that allow packaging of up to 8 Kb foreign DNA in the recombinant virus. The size of JEV expression cassette inserted in RAdEa was ~3.3 Kb which was well within the packaging limits of the recombinant virus. The reason for lower titers of

RAdEa in HEK 293A cells is, thus, not clear. Previously, we found no differences in the levels of expression of membrane-anchored or secretory E protein of JEV when HEK 293A cells were transfected with expression plasmids containing the Ea or Es genes under CMV IE promoter (15). This observation together with our results in the PS cells on E protein synthesis indicates that lower levels of E protein synthesis by RAdEa in HEK 293A cells are related to the low levels of its replication.

#### Example – 11

**Anti-JEV antibody response in mice immunized with RAds:** Groups of BALB/c mice were immunized with RAdEa or RAdEs delivered orally or IM. The antibody response of these mice was compared with those immunized with formalin-inactivated commercial JEV vaccine. Serum samples collected from mice at various time points were assayed for anti-JEV end-point ELISA titers. Figure 4 shows that anti-JEV antibodies were detectable in all immunization groups on day 20 post-immunization and these titers increased further on days 28 and 44 post-immunization following the booster doses. Compared to IM immunization, antibody titers were drastically low in mice immunized orally with RAds. For example, compared to oral immunization,  $1 \times 10^8$  PFU of RAdEs given IM induced ~60-fold higher antibody response on day 44. For both the oral as well as IM immunizations, higher antibody titers were obtained when higher doses of RAd were used. No significant differences were seen in day 44 anti-JEV antibody titers of mice immunized IM with  $7.5 \times 10^5$  PFU of RAdEa or RAdEs. IM immunizations with RAds induced significantly higher antibody titers than those induced by IM inoculation of the vaccine. Thus, the lower dose of RAdEa and RAdEs ( $7.5 \times 10^5$  PFU) gave ~ 60-fold higher antibody titers after the second booster when compared with the titers obtained with the vaccine. At the higher dose of  $1 \times 10^8$  PFU, RAdEs induced ~250-fold higher titers than the vaccine on day 44.

Some investigators have carried out oral immunization of mice with RAds using Sodium bicarbonate buffer to neutralize the acid pH of the stomach (11, 40, 47). However, there are others who have carried out oral immunization of mice with RAds without the use of any buffer (3, 9, 42, 48). We have compared the immunogenicity in mice of RAdEs given orally ( $1 \times 10^8$  PFU) with or without the bicarbonate buffer. Figure 4 shows that no advantage was offered by the use of bicarbonate buffer during oral immunization with RAdEs. In fact, no effect of booster doses was seen when RAdEs was delivered orally using bicarbonate buffer and antibody titers on day 44

post-immunization were lower than in those mice that received the virus without bicarbonate buffer.

**Example – 12**

**Isotype analyses of anti-JEV antibody produced by immunized mice:** In order to analyze the quality of immune responses generated by the RAdS, end-point titers of anti-JEV IgG1 and IgG2a antibodies were determined by ELISA. Figure 5 shows that at lower dose of RAdS given orally ( $3 \times 10^6$  PFU) titers of anti-JEV IgG1 and IgG2a antibodies were below 25. When a higher dose of RAdEs ( $1 \times 10^8$  PFU) was given orally, the majority of antibodies were of IgG1 type; the ratio of IgG1/IgG2a titers in this case was 6.48 indicating a Th2 type of immune response. When RAdS were delivered through IM route, the anti-JEV antibody response was almost exclusively of IgG1 type. In case of mice immunized IM with RAdEa ( $7.5 \times 10^5$  PFU), IgG1/IgG2a titer ratio was 68 and it was 64 in the case of RAdEs ( $7.5 \times 10^5$  PFU)-immunized mice. At higher dose of  $1 \times 10^8$  PFU, RAdEs again induced predominantly IgG1 type of anti-JEV antibodies; the ratio of IgG1/IgG2a titers in this case was 25. These results indicated that RAdEa and RAdEs induced an almost exclusive Th2 kind of immune response in mice when delivered IM. The IM immunization of mice with the vaccine also induced IgG1 dominated antibody response indicating a Th2 type immune response.

**Example – 13**

**JEV neutralizing antibody response in mice immunized with Rads:** Titers of JEV neutralizing antibodies were determined in serum samples obtained from the immunized mice at day 44 post-immunization. Figure 6 shows that oral route of immunization induced very low JEV neutralizing antibodies. Similar to ELISA titers, the JEV neutralizing antibody titers were lower in mice immunized orally with RAdEs plus the bicarbonate buffer compared to titers in those mice immunized with RAdEs without the bicarbonate buffer, although the difference was statistically insignificant. Compared to RAdEa, RAdEs given IM induced higher JEV neutralizing titers and these were enhanced further when higher dose of virus was used for immunization. IM immunization with RAdEs induced significantly higher JEV neutralizing antibody titers than those induced by the vaccine.

**Example – 14**

5 **Cytokine secretion by splenocytes from immunized mice:** Splenocytes prepared from the immunized mice were cultured in presence of JEV and synthesis of IFN- $\gamma$ , IL-4 and IL-5 was studied on each day for the next 4 days. Figure 7 shows that splenocytes from mice immunized with RAdEa or RAdEs by IM route secreted large amounts of IFN- $\gamma$ . Splenocytes from mice immunized with the recombinant viruses through oral route made only small amounts of IFN- $\gamma$ . Similarly, mice immunized with the vaccine made only small amounts of IFN- $\gamma$ . Splenocytes from IM-immunized mice also made moderate amounts of IL-5 which was almost absent in the case of orally immunized mice or mice immunized with the vaccine. IL-4 was not detectable in any of the cases; the detection limit of IL-4 ELISA was 7.8 pg/ml. Similar pattern of cytokine secretion was observed when splenocytes were cultured in presence of JEV E protein

10

**Example – 15**

15 **CTL activity in immunized mice:** To study the generation of memory CTLs, splenocytes from immunized mice were stimulated *in vitro* with JEV and examined for cytotoxic activity against cells infected with JEV. Figure 8 shows the results of CTL assays at various effector to target cell ratios. Thus, mice immunized with RAdEa or RAdEs through IM route showed significant CTL activity. No CTL activity was detectable in mice immunized with RAdEa or RAdEs through oral route. Similarly, unimmunized and Ad5-immunized mice or those immunized with the vaccine showed no CTL activity.

20

**Example – 16**

25 **Mice challenge studies:** Mice immunized with RAds were challenged at day 44 post-immunization by intra-cerebral inoculation of a lethal dose (100 LD<sub>50</sub>) of JEV. These mice were observed for mortality for 3 weeks after the challenge. All mice immunized with 7.5x10<sup>5</sup> or 1x10<sup>8</sup> PFU of RAdEs given IM survived the challenge while none of the unimmunized mice survived. Furthermore, none of the mice immunized IM or orally with 1x10<sup>8</sup> PFU of E1/ E3 Ad5 survived the challenge. About 50-60% protection was seen in mice immunized with 1x10<sup>8</sup> PFU of RAdEs given orally. The level of protection was lower (30%) when mice were immunized orally with lower doses of RAdEs (3x10<sup>5</sup> PFU). The level of protection afforded by RAdEa immunization was very low; about 40% mice survived from those immunized with

30

7.5x10<sup>5</sup> PFU given IM and only about 20% mice survived from the group immunized with 3x10<sup>6</sup> PFU given orally. In a separate experiment, 15 mice were immunized with 1x10<sup>8</sup> PFU of RAdEs and given 2 booster doses on day 21 and 35. When challenged on day 44 post-immunization with 1000 LD<sub>50</sub> of JEV, given intra-cerebral, 100% of the 5 immunized mice survived.

The flavivirus E protein has been the antigen of choice for vaccine development using modern methods of vaccinology such as the DNA vaccination or the use of recombinant virus for antigen delivery (10, 12, 16, 28-31). This has been so because E protein plays an important role in a number of processes, including viral attachment, 10 membrane fusion and entry into the host cell (26). Besides, flavivirus E protein induces virus-neutralizing antibodies and CTLs (14, 14, 15, 22, 23, 34). It has been shown that protection against JEV is mainly antibody dependent, and virus-neutralizing antibodies alone are sufficient to impart protection (19, 32). This was also implied from our 15 previous observation that the formalin-inactivated JEV vaccine, which did not induce CTLs, provided protection to vaccinees against JEV (15). Thus, with a view to develop a recombinant virus-based JEV vaccine, we have constructed RAdS synthesizing JEV E protein.

During replication of JEV, the E protein is expressed on the cell surface. Plasmid DNA vectors have been described that synthesize different forms of the E protein, such as the 20 cytoplasmic, membrane-anchored or secretory (2, 6, 7, 15, 20). These different forms of JEV E protein were shown to induce different kind of immune responses. Similarly, recombinants of vaccinia expressing the secretory E protein of Japanese encephalitis or Dengue viruses were found to be highly immunogenic in mice (14, 27, 37). Previously, we had shown that truncated JEV E protein, where the membrane-anchor sequence had 25 been removed by deletion of the C-terminal 102 amino acids, was actively secreted in the cell surroundings (15). We have now constructed RAdS that synthesize the membrane-anchored or the secretory E protein.

Oral delivery of RAd has been shown to induce humoral and cellular immune responses to the protein encoded by the transgene, however, these responses have 30 usually been weaker compared to those induced by the IM or intra-peritoneal delivery of RAd (21, 35, 42). In the present study too, oral immunization of mice by RAdS resulted in significantly lower anti-JEV antibody titers when compared with the IM route of RAd delivery. Thus, mice immunized IM with 1x10<sup>8</sup> PFU of RAdEs gave

~60-fold higher anti-JEV antibody response than those immunized with the same dose of the virus given orally.

Use of Sodium carbonate buffer to neutralize the pH of the stomach made no perceptible difference to antibody titers when compared with the antibody titers induced by RAdEs given orally without the bicarbonate buffer. In fact, when bicarbonate buffer was used during oral immunization, the booster doses of RAdEs failed to enhance the anti-JEV antibody titers. For RAdEa too, oral delivery resulted in weaker anti-JEV antibody responses compared to the IM delivery of the recombinant. Thus, compared to oral delivery, IM inoculation of  $7.5 \times 10^5$  PFU of RAdEa (which was half the dose given orally) induced ~100-fold higher anti-JEV antibody titers. The antibody titers were dose dependent. Thus higher doses of RAdEs ( $1 \times 10^8$  PFU) delivered orally induced higher anti-JEV antibody titers. These titers were ~4-fold higher than those induced by the commercial vaccine given IM. Importantly, IM inoculation of RAdEa or RAdEs at both the doses tested ( $7.5 \times 10^5$  and  $1 \times 10^8$  PFU) resulted in significantly higher antibody responses than those given by the vaccine;  $1 \times 10^8$  PFU of RAdEs given IM induced ~250-fold higher titer than the vaccine. Similar pattern was reflected in JEV neutralizing antibody titers when oral route of RAd delivery was compared with the IM route although the differences weren't so pronounced. Thus ~20-fold higher JEV neutralizing antibody titers were induced by IM inoculation of  $1 \times 10^8$  PFU of RAdEs compared to oral delivery of the recombinant.

Only statistically insignificant differences were noted in anti-JEV antibody titers induced by  $7.5 \times 10^5$  PFU of RAdEa and RAdEs given IM. However, there was significant difference in the JEV neutralizing antibody titers generated by the two RAdS; a mean JEV neutralizing antibody titer of 10 was obtained when mice were immunized with RAdEa whereas it was 133 when mice were immunized with RAdEs. Higher JEV neutralizing antibody titers were recorded when higher doses of RAdEs were used for immunization. At both the doses tested ( $7.5 \times 10^5$  and  $1 \times 10^8$  PFU) IM inoculation of RAdEs induced significantly higher JEV neutralizing antibody titers than the commercial vaccine. Thus a dose of  $1 \times 10^8$  PFU of RAdEs given IM induced 8-fold higher JEV neutralization titer than the vaccine. These differences in JEV neutralizing antibody titers induced by RAdEa and RAdEs by oral and IM inoculation were reflected in the level of protection afforded by these recombinants to the immunized mice against lethal JEV challenge. Thus both doses of RAdEs inducing JEV

neutralizing antibody titers higher than the vaccine gave 100% protection. Immunization with RAdEs or RAdEa given orally gave only low levels of protection. Challenge experiments indicated that mice immunized IM with the adenovirus synthesizing the membrane-anchored form of JEV E protein did not develop protective immunity whereas those immunized with recombinant synthesizing the secretory form of JEV E protein developed robust anti-JEV protective immunity resulting in 100% protection. These results show that RAd-based JEV immunizations are superior to naked DNA immunizations, which imparted only about 50-60% protection in a mouse challenge model (15). It is interesting that level of protection was similar (50-60%) when mice were immunized with plasmid DNA synthesizing Ea or Es proteins (15) whereas in the present work Es induced significantly superior protective immune response than the Ea protein. This may be related to a more efficient delivery of JEV transgene using RAd than the direct injection of naked plasmid DNA for immunization. Our finding is, however, consistent with reports from others where truncated form of JEV or Dengue E protein (leading to its secretion) was found to be more immunogenic than the membrane-anchored form of the E protein (14, 37).

Poor anti-JEV antibody induction by oral immunization with RAds was also reflected in poor cytokine secretion by splenocytes in presence of JEV. While very little IFN- $\gamma$  was secreted by splenocytes from mice immunized orally with RAdEs or RAdEa, significant amounts of IFN- $\gamma$  were secreted by splenocytes obtained from mice immunized IM with RAdEa or RAdEs. Splenocytes from IM immunized mice also synthesized moderate amounts of IL-5 that was not detectable in cultures of splenocytes obtained from mice immunized orally with RAds. Mice immunized IM with both RAdEa and RAdEs had significant CTL activity, which was undetectable in mice immunized orally with RAds or IM with the vaccine. Oral immunization with RAdEs at lower dose resulted in IgG1 dominated immune responses; ratio of IgG1/IgG2a end-point titers was 6.5. This is consistent with studies on oral immunization of mice with RAd synthesizing rabies glycoprotein where abundance of anti rabies IgG1 was recorded (46). The IM inoculation of RAdEa and RAdEs also resulted in preponderance of IgG1 kind of antibodies. No data could be found in literature on antibody isotypes when adenovirus recombinants are delivered IM. Our results indicating the preponderance of IgG1 type antibodies, secretion of IFN- $\gamma$  and IL-5 by splenocytes and induction of CTLs suggest that IM inoculation of mice with RAd

synthesizing JEV E protein activates both the humoral and the cellular arms of the immune system, and immune responses of both Th1 and Th2 type are induced.

The results presented in this invention show that RAd synthesizing the secretory form of JEV E protein imparted robust immunity in mice against lethal dose of JEV given 5 intra-cerebral. This makes RAdEs a potential candidate vaccine against JEV. Further, safety profile of the vaccine of the instant application was studied. The vaccine is found to be safe for administration. None of the immunized mice showed any obvious complications.

## **Application Project**

< 120 > Title : A recombinant vaccine against Japanese encephalitis virus (JEV) infection and a method ther eof

<130> AppFileReference : IP 1340

<140> CurrentAppNumber : 1516/Del/203

<141> CurrentFilingDate : 2003-12-04

## Sequence

<213> OrganismName : Artificial Sequence

<400> PreSequenceString :





cgggccccgt gagcttgaac ctgaaagaga gttcgacaga atcaatttcg gtgtcgttga 8340  
 cggcgccctg gcgcaaaatc tcctgcacgt tccttgagtt gtcttgatag gcgatctcg 8400  
 ccatgaactg ctgcgtctct tcctcttggatctccgcg tccggctcgc tccacggtgg 8460  
 cggcgaggctc ttggaaaatg cggggcatga gctgcgagaa ggcgttgagg cttccctcg 8520  
 tccagacgcg gctgttagacc acgccccctt cggcatcgcg ggccgcgcatg accacctgcg 8580  
 cgagatttagtgc ctccacgcg cgggcaaga cggcgttagt tgcggcgc tgaaagaggt 8640  
 agttgagggt ggtggcggtg ttgtctcca cgaagaagta cataacccag cgtcgaacg 8700  
 tggattcgtt gatatcccc aaggccctca ggcgtccat ggcctcgtag aagtccacgg 8760  
 cgaagttgaa aaactgggat ttgcgcgcg acacggtaa ctccctcc agaagacgga 8820  
 tgagctcggc gacagtgtcg cgcacccgcg gctcaaaggc tacaggggcc tcttcctt 8880  
 cttaaatctc ctcttcata agggccctccc ctcttccttc ttctggcgcc ggtggggag 8940  
 gggggacacg cggcgacga cggcgacccg ggaggcggtc gacaaagcgc tcgatcatct 9000  
 ccccgccggc acggcgatg gtctcggtg cggcgccggcc gttctcgccg gggcgcatg 9060  
 ggaagacgcc gcccgtatg tcccggttat ggttggcg ggggctgcca tgcggcagg 9120  
 atacggcgct aacgtatcatc ctcaacaatt ttgtgttagg tactccgcg ccgagggacc 9180  
 tgagcgagtc cgcacgcgacc ggatcgaaaa acctctcgag aaaggcgctt aaccagtac 9240  
 agtcgcaagg taggctgagc accgtggcg gccgcgcgg gccgcgtcg ggtttgttc 9300  
 tggcgagggt gctgtgtatg atgttaattaa agtagggcggtt cttagagacgg cggatggcg 9360  
 acagaagcac catgtccctt ggtccggct gctgaatgcg caggcggtcg gccatgcccc 9420  
 aggcttcgtt ttgacatcg cgcaggctt ttagtagtgc ttgcatgac cttttaccg 9480  
 gcacttccttc ttctccccc tcttgtccg catcttcgtc atctatcgct gggcgccgg 9540  
 cggagtttgg cctgttaggtgg cgccttccttc ctccatcg tttgttcccg aagccctca 9600  
 tcggctgaag cagggttagg tcggcgacaa cgcgtccggc taatatggcc tgctgcacct 9660  
 gctgtagggtt aactgtggaaatg tcatccatgt ccacaaacgc gtggatgtcg cccgttgta 9720  
 tgggtgtatg gcatgtggccataaaggccggtt ctgtgtaccc ggctgcgaga 9780  
 gctcggtgtt cctgagacgcg gagaaggccc ttagtgcgtt ttcgtatgtcc 9840  
 gcaccaggta ctgtgtatccc accaaaaagg gccgcgcgg ctggcggttag agggccacg 9900  
 gttaggggtgc cggggctccg gggggcgatg ctccaacat aaggcgatga tatcgtttaga 9960  
 tgtaccttggatccatcggtt atgcggccgg cgggtgtggaa ggcgcgcggaa aagtgcgg 10020  
 cgcgggttcca gatgttgcgcg agccggaaaa agtgcctcat ggtcggttgcg ctctggccgg 10080  
 tcaggcgccgc gcaatcggtt acgtctcgatc gtgcggatggccgatcc 10140  
 ctccgtgtt ctgggtggata aattcgcaag ggtatcatgg cggacgcacgg ggggttgcg 10200  
 cccgtatccg gccgtccgcg gtgtatccatcg cgggttccgcg ccgcgtgtcg aaccagggt 10260  
 tgcgcgtca gacaacgggg gagtgtccctt ttggcttccctt ccaggcgccg ggccgtgtct 10320  
 gcgctgttccctt tttggccac tggccgcgcg cagcgtaacgc ggttaggtcg gaaagcgaaa 10380  
 gcatatgtt gctcgctccc ttagtgcggaa ggggttattttt ccaagggttgcg agtgcggg 10440  
 ccccccgttccg gatgttgcggaa cccgttccctt ccttccatcg cgtcaggagg ggcgcacatcc 10500  
 tgcaagaccc cgcgttgcggaa ttccctccggaa aacagggttgcg agccctttt ttgttttcc 10560  
 cagatgcac cgggtgtcg cgcacatgcgc ccccttccttc agcaggccgcgca agagcaagag 10620  
 cagcgccgcgaa catgcggggcc accccctccctt ccttccatcg cgtcaggagg ggcgcacatcc 10680  
 gcggttgcgcg cggcaggcaga tgggtgattac gaaccccccgcg ggcgcggccgc ccggcactac 10740  
 ctggacttgg aggaggccgaa gggccctggcg cggtaggag cgccttccttc tgagcggcac 10800  
 ccaagggttgc agtgcacgcg tgatgcgtt gggcgatcg tgccgcggca gacccgtttt 10860  
 cgcgcacccgcg agggagaggaa gcccgaggag atgcgggatc gaaaggatcc cgcaggccgc 10920  
 gagctcgccgc atggcccttggaa tcggcgacgg tttgtcgccgcg aggaggactt tgagcccgac 10980  
 gcgccgcacccgcg ggatgttgcgcg cgcgttgcgcgca cacgtggccgg cccgcgcacccgc 11040  
 tacgacgttgcg cggatgttgcgcg aaccccccgcg ggcgcggccgc ccggcactac 11100  
 acgctgttgg cgcgcgcggaa ggtggctata ggactgtatgc atctgtggaa ttgtgtatgc 11160  
 gcgctggccgc aaaaacccaaa tagcaaggccgc ctcatggccgc agtgcgttcttataatgtgcac 11220  
 cacagcaggccgc acaacgcggc attcaggat ggcgtgttccaa acatagtgaa gcccggggc 11280

cgctggctgc tcgatttgat aaacatccctg cagagcatag tggcagggcggcgcgtt 11340  
agccctggctg acaagggtggc cgccatcac tattccatgc tttagctggg caagtttac 11400  
gccccagaata accatccatc cccttacgtt cccatagaca aggaggtaaa gatcgagggg 11460  
ttctatgc gcacggcgct gaaggtgtt accttgcggc acgaccctggg cgtttatgc 11520  
aacgagcgc tccacaaggc cgtgagctg agccggcggc gcgagctcg cgaccgcgag 11580  
ctgatgcaca gcctgaaag ggcccgtggc ggcacgggca gccggatag agaggccgag 11640  
tcctacttgc acgccccggc tgacctgcgc tggcccca gccgacgcgc cctggaggca 11700  
gctggggccg gacctggctt ggcggggca cccgcgcgc ctggcaacgt cggccggcgt 11760  
gagaaatatg acgaggacga tgagtacag ccagaggacg gcgagtaacta agcggtgtatg 11820  
tttctgtatca gatgtatca gacgcacgg accccggcggt gcccggcggc ctgcagagcc 11880  
agccgtccgg ccttaactcc acggacgact ggcgcaggat catggaccgc atcatgtcg 11940  
tgactgcgcg caatctgtac gcgttccggc agcagccgc ggcacccgg ctctccgca 12000  
ttctggaaagc ggtgggtccgg ggcgcgcgc accccacgcg cggaaagggt ctggcgatcg 12060  
taaacgcgcg ggcggaaaac agggccatcc ggcccggacga ggcggccctg gtctacgacg 12120  
cgctgcctca ggcgtggct ctttacaaca gccgcacgt gcagaccaac ctggaccggc 12180  
tggtgggggaa tggcgcgag gccgtggcgc acgtgagcg cgcgcagcag caggcacc 12240  
tgggtccat ggttgcacta aacgccttcc tgagtacaca gccgcaca gtcggccggg 12300  
gacaggagga ctacaccaac ttgtgagcg cactgcggct aatggtgact gagacaccgc 12360  
aaagtgggggt gtaccatgtt gggccagact atttttcca gaccgtaga caaggcctgc 12420  
agaccgtaaa cctgagccag gctttcaaaa acttgcaggg gctgtggggg stgcgggctc 12480  
ccacaggcga cgcgcgcacc gtgtctagct tgctgcgc gcaactcgcgc ctgttgcgtc 12540  
tgctaatacg gccccttccgc gacagtggca gctgtcccg ggacacatac ctgggtact 12600  
tgctgacact gtaccgcgag gccataggc acggcgtatg ggacgagcat actttccagg 12660  
agattacaag tggcgcgcg ggcgtggggc aggaggacac gggcagcctg gaggcacc 12720  
taaactaccc gctgacccaaat cggccggcaga agatccccctt gttgcacagt ttaaacagcg 12780  
aggaggagcg catttgcgc tacgtgtcgc agagctgtt gcttaacctg atgcgcgacg 12840  
gggttaacgcg cagcgtggcg ctggacatga cggcgcgc gatggaccc ggcgtatgt 12900  
cctcaaaaccg gccgtttatc aaccgcctaa tggactactt gcatgcgcg gccgcgtga 12960  
accccgagta ttccaccaat gccatcttgc accccgcactg gctaccgc gcttgcgtt 13020  
acaccggggg attcgagggtt cccgagggtt acgtatggg cctctgggac gacatagacg 13080  
acagcgttgtt ttcccccgc ggcgcggaccc tgcttagatg tcaacagcgc gaggcggcag 13140  
aggccggcgt gcgaaaggaa agcttccgc ggcacggc gttgtccgtat ctggcgctg 13200  
cgccccccgcg gtcagatgtt agtagcccat ttccaaactt gatagggtt ctatccagca 13260  
ctcgaccac cccgcgcgcg ctggcggcgg aggaggagta cctaaacaaac tcgcgtctc 13320  
agccgcagcg cggaaaaaaat ctgcctccgg cattttccaa caacgggata gagagccctag 13380  
tggacaagat gagtagatgg aagacgtacg cgcaggagca cagggacgtg ccaggcccgc 13440  
gcccgcacc cctgtgttca accgcacgacc gtcaggggg tctgggtgtgg gaggacgtg 13500  
actcggcaga cgacagcgc gtcctggatt tggggaggag tggcaaccccg tttgcgcacc 13560  
ttcgccccag gctgggggaga atgtttaaa aaaaaaaaaa gcatgtatca aaataaaaaa 13620  
ctcaccacccg ccatggcacc gaggcttgg tttctgtat tccctttagt atgcgcgcg 13680  
cgccgtatgtt tgagggaaatg cctcccttccctt cctacggagag tgggtgtggc gccgcgcgc 13740  
tggccggcggc gctgggttctt ccccttcgtat ctcccttgcg cccgcctt gtcgcctccgc 13800  
ggtagccgtg gcttacccggg gggagaaaca gcatccgtt cttctgtat gcaaccctat 13860  
tcgacaccac ccgtgtgtac ctgggtggaca acaagtcac ggatgtggca tccctgtact 13920  
accagaacga ccacagcaac ttctgtatccatccatca aaacaatgtc tacagcccg 13980  
gggaggcgaag cacacagacc atcaatcttgc acgaccggc gcactggggc ggcgcacc 14040  
aaaccatccctt gcataccacatg tgaacggatg catgtttacc aataagtta 14100  
aggcgcgggtt gatgggtgtcg cgttgcctt ctaaggacaa tcaggtggag ctgaaatacg 14160  
agtgggtggaa ttccacgcgtc cccggggcactactccgaa gaccatgacc atagacc 14220  
tgaacaacgc gatcgtggag cactacttgc aagtggggcag acagaacccggg gttctggaaa 14280



cgggcggcat gcgtcgtcgc caccacggc ggccggcgcg gtcgcaccgt cgcatcgcg 17340  
gcccgtatccct gcccccttattccactga tcgcccggc gattggcgcc gtgcccggaa 17400  
ttgcacatccgt ggccttgcag ggcgcagagac actgattaaa aacaaggtagc atgtgaaaa 17460  
atcaaaataa aaagtcttgcg ctctcacgt cgcttggtcc tctaactatt ttgtagaatg 17520  
gaagacatca actttgcgtc tctggccccc cgacacggct cgccgcggc catggaaac 17580  
tggcaagata tcggcaccag caaatatggc ggtggccgc tcaactgggg ctcgtgtgg 17640  
agcggcattaaa aaaaatttcgg ttccaccgtt aagaactatg gcagcaggc ctggaaacgc 17700  
agcacaggcc agatgctgag ggataaggtaa aagagcaca atttccaaca aaaggtagt 17760  
gatggccctgg cctctggcat tagcggggtg gtggacctgg ccaaccaggc agtgc当地 17820  
aagattaaca gtaagcttgc tcccccctt cccgttagagg agcctccacc ggccgtggag 17880  
acagtgtcctc cagaggggcg tggcggaaaag cgtccgcgc cgcacaggga agaaaactctg 17940  
gtgacgcaaa tagacgagcc tccctcgatc gaggaggcac taaagcaagg cctggccacc 18000  
acccgtccca tcgcgcctt ggctaccggg gtgtctggcc agcacadacc cgtacgtg 18060  
gacctgcctc ccccccggc caccggcagc aacactgtgc tgccaggccc gaccggcgtt 18120  
gttgtaaccctt gtccttagcgc cgcgttcccg cgcgcgcgc ccagggttcc ggcgttgc 18180  
cgccgcgttcccg ccagtggcaaaatggc aactgaaca gcatctgtgg tctgggggtg 18240  
caatcccttgc agcgcgcacg atgcttgc tgcataactg gtcgtatgtg tgcgtatgt 18300  
gcgtccatgt cgccgcgaga ggagctgtg agccggcgcg cgcggcttcc ccaagatggc 18360  
taccccttgc atgatggccgc agtggcttgc catgcacatc tggggccagg acgcctcgga 18420  
gtacctgagc cccgggttgc tgcatgttgc cgcgcgcacc gagacgtact tcaggctgaa 18480  
taacaaggtaa agaaacccca cgggtggcgc tacgcacgac gtgaccacag accggccca 18540  
gcgttttgc cttgcgttca tccctgtgg cctgtggatg actgcgtact cgtacaaggc 18600  
gcgggttccacc ctatgttgc ggtataaccg tggctggac atggcttca cgtacttga 18660  
catccggccgttgc ctatgttgc gggggccctac tttaagccctt tactctggca ctgccttcaa 18720  
cgccctggcttcccg cccaaatcc ttgtggatgg gatgaagctg ctactgtct 18780  
tgaatataaac cttagaagaag aggacgtatc caacgaagac gaagtagatc agcaagctg 18840  
gcagcaaaaa actcacgtt tggggcaggc gcccatttttctt ggtataataa ttacaaggaa 18900  
gggttattcaat atagggttgc aaggtcaaac acctaataat gcccataaaa catttcaacc 18960  
tgaacctcaat ataggagaat ctatgttgc tggatggatgg aatcatgt cagttttgg 19020  
agtccctaaaa aagactaccc caatgaaacc atgttacgtt tcataatgc aacccacaaa 19080  
tggaaatggatggc gggcaaggc ttcttgcataa gcaacaaaat gggaaatgttcaatgg 19140  
ggaaatgttcaat ttttctcaat ctatgttgc agccgcaggc aatgggtata actgtactcc 19200  
taaagtgttgc ttgttgcataa gggatgttgc ttttttttttgcataatggatgg 19260  
catggccactt attaaggaaat gtaacttgc agaactatg gggcaacaaat ctatggccaa 19320  
caggccctaaat tacatgttgc tttagggatgg aatgggttgc ttttttttttgcataatgg 19380  
gggttaatatg ggttttgc tggccaaaggc atgcgttgc aatgttgc ttttttttttgcataatgg 19440  
agacagaaaac acagagcttcc cataccagct tttgttgc tccatgttgc atagaaccag 19500  
gtacttttctt atgttgcataatggcaggc ttttttttttgcataatggatgg 19560  
aaatcatgttgc ttttttttttgcataatggatgg aatgggttgc ttttttttttgcataatgg 19620  
tacagagacttccatgttgc ttttttttttgcataatggatgg 19680  
tttttttttgcataatggatgg aatgggttgc ttttttttttgcataatggatgg 19740  
caatctaaat gcccacccgtt ggagaaaattt cctgttgc ttttttttttgcataatggatgg 19800  
cgacaagcttcaat ggttgc ttttttttttgcataatggatgg 19860  
ctatgttgc ttttttttttgcataatggatgg 19920  
acgttgc ttttttttttgcataatggatgg 19980  
cctgttgc ttttttttttgcataatggatgg 20040  
gcctcgttgc ttttttttttgcataatggatgg 20100  
gttgc ttttttttttgcataatggatgg 20160  
gggttgc ttttttttttgcataatggatgg 20220  
ggcccccacac acccccttccat cgttgc ttttttttttgcataatggatgg 20280

cttaacgac tatctctcg ccgccaacat gcttaccct atacccgca acgttaccaa 20340  
 cgtgcccata tccatccccct cccgcaactg ggccggctttc cgccggctggg cttcacgcg 20400  
 ccttaagact aaggaaaccc catactggg ctcgggtac gaccctatt acacctactc 20460  
 tggctctata ccctacccatg atggaaacctt ttacctcaac cacaccccta agaagggtggc 20520  
 cattacctt gactcttctg tcagctggcc tggcaatgac cgccctgctta cccccaacga 20580  
 gttgaaatt aagcgctcg ttagccccggg gggttacaac gttgcccagt gtaacatgac 20640  
 caaagactgg ttccctggatc aaatcttagc taactataac attggcttacc agggcttcta 20700  
 tatcccagag agtatacagg accgcatgta ctcccttcc agaaacttcc agcccatgag 20760  
 ccgtcaggtg gtggatgata ctaatacaca ggactaccaa cagggtggca tcctacacca 20820  
 acacaacaac tctggatttg ttggcttaccct tgccccccacc atgcgcgaag gacaggccca 20880  
 ccctgctaac ttccccatc cgcttatagg caagaccgca gttgacagca ttacccagaa 20940  
 aaagtttctt tgccatcgca ccctttggcg catccattc tccagtaact ttatgtccat 21000  
 gggcgcaactc acagacccctgg gccaaacccct tctctacgca aactccgccc acgcgttgc 21060  
 catgactttt gaggtggatc ccatggacga gcccacccctt cttatgttt tggttgaagt 21120  
 cttingacgtg gtccgtgtgc accagccgca ccgcggcgtc atcgaaacccg tgtacctg 21180  
 cacgccttc tccggccggca acgcccacaac ataaagaacg aagcaacatc aacaacagct 21240  
 gcccattgg gctccatgtg gcaggaaactg aaagccattg tcaaaagatct tgggttggg 21300  
 ccatatttt tggccaccta tgacaaggc ttccaggct tgggttcc acacaagctc 21360  
 gcctgcgcca tagtcaatac ggccggcgtc gagactgggg gcgtacactg gatggccctt 21420  
 gcctggaaacc cgcactaaa aacatgtac ctcttgcgc cctttggctt ttctgaccag 21480  
 cgactcaagc aggttttacca gttttagtac gagtcaactcc tgccggtag cgccattgt 21540  
 tctcccccgg accgctgtat aacgctggaa aagtccaccc aaagcgtaca gggggcccaac 21600  
 tcggccgcct gtggactatt ctgctgcatg ttctccacg cttttggccaa ctggcccca 21660  
 actcccatgg atcacaaccc caccatgaac ctattacgg gggtaacccaa ctccatgctc 21720  
 aacagttcccc aggtacagcc caccctgctg cgcaaccagg aacagcttca cagttctg 21780  
 gagcgocact cgccctactt ccgcagocac agtgcgcaga ttaggagcgc cactttttt 21840  
 tgcacttgcgaaaatgt aaaaatgt actagagaca ctttcaataa aggcaaatgc 21900  
 ttatattgt acactctgg gtgattttt acccccaccc ttggcgtctg cgccgtttaa 21960  
 aaatcaaagg ggttctggcg cgcatcgta tgcgccactg gcagggacac gttgcgatc 22020  
 tgggttttag tgctccactt aaactcaggc acaaccatcc gccggcagctc ggtgaagttt 22080  
 tcaactccaca ggctgcgcac catccaac gcgtttagca ggtcggccgc cgatatctt 22140  
 aagtcgacttggggccctt gcccctgcgcg cgccggatgc gatacaccagg gttgcagcac 22200  
 tggaaacacta tcagccggg gtgggtcagc ctggccagca cgcttgcgc ggagatcaga 22260  
 tccgcgttca ggttccgcgttgcgtcagg gccaacggag tcaactttgg tagtgcctt 22320  
 cccaaaaagg ggcgtgccc aggctttagt ttgcactcgc accgtatgg catcaaagg 22380  
 tgaccgtgccc cggctctggc gtttaggatc agcgcctgca taaaagccctt gatctgctt 22440  
 aaagccaccc ggccttgcg gccttccagag aagaacatgc cgcaagactt gcccggaaac 22500  
 tgattggccg gacaggccgc gtcgtgcacg cagcaccttgc cgctgggtt ggagatctgc 22560  
 accacatttc ggccttccaccc gtttccacg atcttggctt tgcttagactt ctccctcgc 22620  
 ggcgcgttcccg ctttttcgtt cgttccatcc atttcaatca cgttccctt atttacata 22680  
 atgcctccgtt gtagacactt aagtcgcctt tcgttccatcc cgcagccgtt cagccacaac 22740  
 ggcgcgttcccg tggctctggcgtt atgccttgcgtt gtcaccccttgc caaactgactt caggtacgccc 22800  
 tgcaggaaatc gcccctatcat cgttccatcc cgttccatcc gtttccatcc tggtaaggtt cagtcgcac 22860  
 ccgcgggtgtt ctcgttccatcc ccaggcttgcgtt cataccggccgc ccaggacttcc cacttggc 22920  
 ggcgtatgtt tgaagttccgc cttagatgc ttatccacgt ggtacttgcgc catcagcgcg 22980  
 cgcgcgttcccg ctttttcgtt cgttccatcc cgttccatcc gacacgtatcc gacacttcc cgggttccatcc 23040  
 accgtatattt cacttccgc ttcgttccgc ttcgttccatcc cgttccatcc cgttccatcc 23100  
 cgcgcgttcccg ggttccatcc attcgttccgc cgcacttgcgtt gtcaccccttgc ttttccatcc 23160  
 ttgatttagca cccgggtt gctgaaaccc accatgttgc ggcgcacatc ttcttccatcc 23220  
 tccctcgatc ccaacgttccgc ttcgttccatcc cgttccatcc cgttccatcc cgggttccatcc 23280

ttctttttct tcttggcgc aatggccaaa tccgcccgg aggtcgatgg ccgcgggctg 23340  
ggtgtgcgcg gcaccagcgc gtcttgat gagtcttcct cgtccctcgg a ctcgatacgc 23400  
cgccatcc gctttttgg gggcgcggg ggaggcggcg ggcacgggga cggggacgac 23460  
acgtcccca tggttgggg acgtcgccgc gcaccgcgc cgccgtcggg ggtggttcg 23520  
cgctgctct ctccccact ggccatttcc ttctcctata ggcaaaaaa gatcatggag 23580  
tcagtcgaga agaaggacg cctaaccgc cccctctgagt tcgccaccac cgccctccacc 23640  
gatgcccca acgcccata cacccccc gtcgaggcac ccccgctga ggaggaggaa 23700  
gtgattatcg agcaggaccc aggtttgt a g c g a a g a c g acgaggaccc ctcagtagcca 23760  
acagaggata aaaagcaaga .ccaggacaac gcagaggcaa acgaggaaca agtcggcgg 23820  
ggggacgaaa ggcattggcga ctacctagat gtggagacg acgtgctgtt gaagcatcg 23880  
cagcgcagg ggcattt ctgcgacgc ttgcaagagc gcagcgatg gcccctcggc 23940  
atagcgatg tcgccttgc ctacgaacgc cacctatttct caccgcgcgt accccccaaa 24000  
cgccaagaaa acggcacatg cgagccaaac ccgcgcctca acttctacc cgtatttgcc 24060  
gtgccagagg tgcttgcac ctatcacatc ttttccaaa actgcaagat acccctatcc 24120  
tgccgtgcca accgcgcgc agcggacaag cagctggct tgcggcagg cgctgtcata 24180  
cctgatatcg cctcgctaa cgaatgtc aaaaatcttgg agggcttgc acgcgcgag 24240  
aagcgcgcgg caaacgcctc gcaacaggaa aacagcgaaa atgaaagtca ctctggagtg 24300  
ttggtggAAC tcgagggtga caacgcgcgc ctgcgtac taaaacgcg catcgaggc 24360  
accacttgc ctaaccggc acttaaccta ccccccagg tcatgagcac agtcatgagt 24420  
gagctgatcg tgccgcgtgc gcagccctg gagagggatg caaatggca agaacaaca 24480  
gaggagggcc tacccgcgtg tggcgcgcg cagctgcgc gctggctca aacgcgcgag 24540  
cctgcgcact tggaggagcg acgcaaaacta atgatggcg cagtgctgtt accgtggag 24600  
cttgagtgc tgcagcggtt cttingctgac ccggagatgc agcgaagct agaggaaaca 24660  
ttgactaca ctttcgaca gggctacgt cgcaggcgt gcaagatctc caacgtggag 24720  
ctcgcaacc tggctctca ctttggatt ttgcacgaaa accgccttgg gcaaaacgtg 24780  
cttatttca cgctcaaggg cgaggcgcgc cgccactacg togcgcactg cgtttactta 24840  
tttctatgtt acacctggca gacggccatg ggctttggc agcagtgtt ggaggagtgc 24900  
aacctcaagg agtgcgcgaa actgctaaag caaaacttgc aggacatgc gacggccctc 24960  
aacagcgct ccgtggccgc gcacccggc gacatcattt tccccaacg cctgcttaaa 25020  
accctgcaac agggctgcgca agacttcacc agtcaaagca tggcacttcc ctttaggaac 25080  
tttatcttag agcgcctcagg aatcttgc cccacctgcgt gtgcacttcc tagcacttt 25140  
gtgccattt a g t a c c g c g a atgcctccg ccgttttggg gccactgca ccttctgcag 25200  
ctagccaaact accttgcctt ccactctgac ataatggaaag acgtgagcgg tgacggctca 25260  
ctggagtgtc actgtgcgtg caacccatgc accccgcacc gctccctgtt ttgcaattcg 25320  
cagctgccta acgaaagtca aattatcggt acctttgagc tgcagggtcc ctgcctgac 25380  
gaaaagtccg ccgtccggg gttgaaactc actccggggc tggacgcgtt ggcttaccc 25440  
cgcaaaatgg tacctgagga ctaccacgc cccggatggat ggttctacga agaccaatcc 25500  
cgccgcctt atgcggatgtt accgcgtgc gtcattacc accggccatc tcttggccaa 25560  
ttgcaagccca tcaacaaggc ccgccaagag ttctgctac gaaagggacg gggggtttac 25620  
ttggacccccc agtccggcga ggagctcaac ccaatcccccc ccgcgcgcgca gcccattac 25680  
cagcgcgcgc gggcccttgc ttcccaggat ggcacccaaa aagaagctgc agctgcccgc 25740  
gccacccacg gacgaggagg aatactggga cagtcaggca gaggaggtt tggacgagga 25800  
ggaggaggac atgatggaaag actggagag cctagacgag gaagctccg aggtcgaga 25860  
gggtgcagac gaaacaccgt caccctcggt cgcattccccc tgcggcgcgc cccagaaatc 25920  
ggcaaccgggt tccagcatgg ctacaaccc cgcctctcg ggcgcgcgg cactgcccgt 25980  
tcgcgcaccc aaccgttagat gggacaccac tggacccagg gccggtaatg ccaagcagcc 26040  
ggccgcgtt gccaagacgca aacaacagcg ccaaggctac cgcctcatggc gcgggcacaa 26100  
gaacgcata gttgcttgc tcaagactg tggggcaac atctccctcg cccggcctt 26160  
tcttcctac catcacggc tggccctccc ccgtacatc ctgcattact accgtcatct 26220  
ctacagccca tactgcacccg gcccgcgcgg cagcaacagc agcggccaca cagaagcaaa 26280

ggcgcaccgga tagcaagact ctgacaaaagc ccaagaaaatc cacagcgccg gcagcagcag 26340  
gaggaggagc gctgcgtcg cgccccaaacg aaccctgtatc gacccgcgag cttagaaaaca 26400  
ggattttcc cactctgtat gctatatttc aacagagcag gggccaagaa caagagctga 26460  
aaataaaaaa caggctctcg cgatccctca cccgcagctg cctgtatcac aaaagcgaag 26520  
atcagcttcg gcgcacgtg gaagacgcgg aggctctt cagtaataac tgccgcgtga 26580  
ctcttaaggag ctatgttcgc gccccttctc aaatthaagc gcgaaaacta cgtcatctcc 26640  
agcggccaca cccggcgcca gcacccgttg tcagcgcctat gagcaag gaaattccca 26700  
cgccctacat gtggagttac cagccacaaa tgggacttgc ggctggagct gccaagact 26760  
actcaacccg aataaactac atgagcgcgg gacccacat gatatcccg gtcaacggaa 26820  
tacgcgcccc cggaaaccga attctcttgc aacaggcggc tattaccacc acacctcgta 26880  
ataacctta tccccgttagt tggcccgctg cccgtgtca ccagggaaagt cccgtccca 26940  
ccactgttgtt acitcccgaga gacgcccagg cggaaactca gatgactaac tcagggcg 27000  
agcttgcggg cggcttcgt cacaggggtgc ggtccccgg gcagggtata actcacctga 27060  
caatcagagg gcgagggtt cagctcaacg acgagtcggt gagctcctcg ctgtgtctcc 27120  
gtccggacgg gacatttcg atcggccggc cggccgctc ttcatcaag cctcgtcagg 27180  
caatcctaac tctgcagacc tctgcctctg agccgcgcctc tggaggcatt ggaactctgc 27240  
aatttattga ggagtttg tcatcggtct acitthaaccc ttctcgaaa cctccggcc 27300  
actatccggaa tcaattttt cctaactttg acgcccgtaaa ggactcggcg gacggctacg 27360  
actgaatgtt ataagttcc tgcctatccgc acccactatc ttcatgttgt tgcatgatgaa 27420  
gcfgcgaaga ccgtctgaag ataccttcaa ccccgtgtat ccatatgaca cggaaaccgg 27480  
tccctcaact gtgccttttcc ttactccctcc ttgttatcc ccaatgggt ttcaagagag 27540  
tccccctggg gtactcttgc tgcctatc cgaacctcta ttacccatca atggcatgt 27600  
tgccgtcaaa atgggcaacg gctctcttgc ggacgaggccc ggcacccatca cctccaaaaa 27660  
tgcacccact gtgagccac ctctcaaaaaa aaccaagtca aacataaacc tggaaatatc 27720  
tgcacccctc acagttacat cagaagccct aactgtggct ggcgcgcac ctctaatgg 27780  
cgccggcaac acactcaaca tgcacatcaca ggccccgtca acgggtcag actccaaact 27840  
tagcatgtcc acccaaggac cccctacatgt gtcagaaggaa aagctagccc tgcaaaacatc 27900  
aggccccctc accaccacccg atagcagttac ccttactatc actgccttcac cccctcta 27960  
tactgccact ggtagtttgg gcattgtactt gaaagagccctt attatacac aaaaatggaaa 28020  
actaggacta aagtacgggg ctcccttgc tgcacacagac gacctaataaca ctttgaccgt 28080  
agcaactgtt ccagggttgc ctatataaa tacttccctg caaactaaag ttactggagc 28140  
cttgggtttt gattcacaag gcaatatgca acttaatgtt gcaaggaggac taaggattga 28200  
ttctcaaaac agacgccttacttgcgtt tagttatccg ttgtatgtc aaaaccaact 28260  
aaatctaaga cttaggacagg gccccttttataaaactca gcccacaact tggatattaa 28320  
ctacaacaaa ggcctttact tgttacagc ttcaaaacaat tccaaaagc ttgagggtt 28380  
cctaagcact gccaagggggt tgatgtttga cgctacagcc atagccattatgcaggaga 28440  
tggcccttgcatttgcgtt ctaatgcacc aaacacaaat cccctcaaaa caaaatgg 28500  
ccatggcccttca gaatttgatttgc caacacaggc tatggttctt aaacttagggaa ctggcccttag 28560  
tttgcacgc acagggttgc ttacagtagg aaacaaaaat aatgataagc taactttgt 28620  
gaccacacca gctccatctc ctaactgttagt actaaatgca gagaagatg ctaactac 28680  
tttgccttca acaaaatgttgc gcatgttacttgcgtt gcaaggatgtt 28740  
aggcagtttgc gctccatatatcttgcgttacttgcgtt tcaacttgcgtt gcaaggatgtt 28800  
cgaaaatggatgttgcgttacttgcgttacttgcgtt gcaaggatgtt 28860  
tggagatcttgcgttacttgcgttacttgcgtt gcaaggatgtt 28920  
agcttacatca acatctcacttgcgttacttgcgtt gcaaggatgtt 28980  
aaacggagac aaaactaaac ctgtacacttgcgttacttgcgtt gcaaggatgtt 29040  
aggagacaca acatctcacttgcgttacttgcgtt gcaaggatgtt 29100  
ctacatcaat gaaatatttgcgttacttgcgttacttgcgtt gcaaggatgtt 29160  
agaatcttgcgttacttgcgttacttgcgtt gcaaggatgtt 29220  
attttcatt ctagtgcgttacttgcgttacttgcgtt gcaaggatgtt 29280

atcaaactca cagaacccta gtattcaacc tgccacctcc ctcccaacac acagagtaca 29340  
 cagtccttc tccccggctg gccttaaaaa gcatcatatc atggtaaca gacatattct 29400  
 tagtgttat attccacacg gttccctgtc gagccaaacg ctcatcgtg atattaataa 29460  
 actccccggg cagctcactt aagtcatgt cgctgtccag ctgcgtagcc acaggctgct 29520  
 gtccaacttg cggttgctta acggcgccg aaggagaagt ccacgcctac atggggtag 29580  
 agtcataatc gtgcacagg atagggcggt ggtgcgtcag cagcgcgcg ataaaactgt 29640  
 gcccgcgcg ctccgtcctg caggaataca acatggcagt ggtctctca gcgatgattc 29700  
 gcacccgcgcg cagcataagg cgcctgtcc tccggcaca gcagcgcacc ctgatctac 29760  
 ttaaatcgc acagtaactg cagcacagca ccacaatatt gttcaaaatc ccacagtgc 29820  
 aggccgtgta tccaaagctc atggcgaaaa ccacagaacc cacgtggcca tcataccaca 29880  
 agcgccgtta gattaagtgg cgacccctca taaacacgct ggacataaac attaccttt 29940  
 ttggcatgtt gtaattcacc acctcccggt accatataaa cctctgatta aacatggcgc 30000  
 catcaccac catctaaac cagctggcca aaacctgccc gccggctata cactgcagg 30060  
 aaccgggact ggaacaatga cagtggagag cccaggactc gtaaccatgg atcatcatgc 30120  
 tcgtcatgt atcaatgttgc acacacgtc catacacttc ctctaggat 30180  
 caagctcctc ccgcgttaga accatatccc agggaaacaac ccattctga atcagcgtaa 30240  
 atcccacact gcagggaaaga cctcgcacgt aactcactt gtgcattgtc aaagtgttac 30300  
 attcggcag cagcggatga tcctccagta tggtagcgcg ggttctgtc tcaaaaggag 30360  
 gtagacgatc cctactgtac ggagtgcgcg gagacaaccc agatcgtt ggtcgtatg 30420  
 tcatgccaat tggAACGCGC gacgttagtca tatttcctga agccaaacca ggtgcggcg 30480  
 tgacaaacag atctgcgtct ccggctctgc cgcttagatc gctctgtta gtagttgtag 30540  
 tatatccact ctctaaagc atccaggcgc cccctggctt cgggttctat gtaaactcct 30600  
 tcatgcgcg ctgcctgtat aacatccacc accgcagaat aagccacacc cagccaaacct 30660  
 acacattcgt tctgcgagtc acacacggga ggagcgggaa gagctggaaag aaccatgttt 30720  
 ttttttttat tccaaaagat tatccaaatca ctcggatgtaa agatcttata agtgaacgcg 30780  
 ctccccctcg gtggcggttcaactctac agccaaagaa cagataatgg cattttgtaaag 30840  
 atgttgcaatc atggcttcaaa aaggccaaac ggccctcagc tccaaatgttgc cgtaaaggct 30900  
 aaaccttca gggtaatct cctctataaa cattccagca ccttcaacca tgcccaata 30960  
 atttcatct cgcacccctc tcaatatatc tctaagccaa tcccgatat taagtccggc 31020  
 cattgtaaaa atctgcgttca gagegccttc cacccctcagc ctcaaggcgc gaatcatgtat 31080  
 tgccaaaaat cagttccctc acagacccctgt ataagattca aaagcggaaac attaacaataa 31140  
 ataccgcgtat cccgttagtgc ctttcgcagg gccagctgaa cataatcgtg caggtctgc 31200  
 cggaccagcg cgccacttc cccgcaggaccatgc aagaacccac actgattatg 31260  
 acacgcatac tcggagctat gctaaccagc gtagccccga tggatcttgc ttcgtatggc 31320  
 ggcgatataa aatgcaggt gtcgtcaaa aatcaggca aagcctcgcg caaaaaagaa 31380  
 agcacatcgt agtcatgtc atgcagatataa aggccaggtaa gctccggaaac caccacagaa 31440  
 aaagacacca tttttctcaaaacatgttgc ggggtttct gctataaacac aaaataaaat 31500  
 aaaaaaaaaa catttaaaca tttagaaggct gtcttacac agggaaaaaca acccttataa 31560  
 gcataagacg gactacggcc atgcggcgt gaccgtaaaaaa aactggtca ccgtgattaa 31620  
 aaagcaccac cgacagctcc tcggatgttgc cggaggatcat aatgtaaacatcgttca 31680  
 catcagggttgc attcacatcg gtcgtgtca aaaaagcgcacc gaaatagccc gggggaaatc 31740  
 ataccgcgtat cccgttagtgc aacattacag cccctcatagg aggtataaca aaattaatag 31800  
 gagagaaaaa cacataaaca cctgaaaaac cttccgtccat aggccaaataa gcaaccctccc 31860  
 gctccagaac aacatacagc gttccacag cggcagccat aacagtcgc ctaccatgt 31920  
 aaaaagaaaaa ccttataaaa aacacccactt cgcacacggca ccacgtcaat cgtcacatgt 31980  
 gtaaaaaagg gccaagggtca gagccaggat atataggact aaaaatgtac gtaacgggtt 32040  
 aagtccacaa aaaaacccca gaaaaccgcg cgcgaaccta cgcccgaaaaa cgaaagccaa 32100  
 aaaaacccca acttcctcaatcgtcactt ccgtttccctt acgttacgtc acttccctt 32160  
 ttaagaaaaac tacaattcccc aacacataca agttactccg ccctaaaacc tacgtcacc 32220  
 gccccgttcc cacgcggccgcg gccacgtcacttccaccc ccctcattat catattggct 32280



tagttaatta acgttaatta acatcatcaa taatatacct tattttggat tgaagccaat 35340  
atgataatga ggggggtggag ttgtgacgt ggccgcggggc gtgggaacgg ggcgggtgac 35400  
gtatgtgtgt ggcggaaagtg tgatgttgca agtgtggcgg aacacatgta agcgacggat 35460  
gtggcaaaag tgacgtttt ggtgtgcgcc ggtgtacaca ggaagtgaca atttcgcgc 35520  
ggttttaggc ggatgttgta gtaaatttgg gcgtAACCGA gtaagatttg gccattttcg 35580  
cggaaaaact gaataagagg aagtgaaatc tgaataattt tgtgttactc atagcgcgt 35640  
atctctagca t 35651

<212> Type : DNA

<211> Length : 35651

SequenceName : SEQ ID No.1

SequenceDescription :

**Custom Codon**

---

- Sequence Name : SEQ ID No.1

**REFERENCES**

1. Andersen, M. M. and T. Ronne. 1991. Side-effects with Japanese encephalitis vaccine. *Lancet* **337**:1044.
- 5 2. Ashok, M. S. and P. N. Rangarajan. 2000. Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies. *Vaccine* **18**:68-75.
- 10 3. Both, G. W., L. J. Lockett, V. Janardhana, S. J. Edwards, A. R. Bellamy, F. L. Graham, L. Prevec, and M. E. Andrew. 1993. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. *Virology* **193**:940-950.
- 15 4. Casimiro, D. R., A. Tang, L. Chen, T. M. Fu, R. K. Evans, M. E. Davies, D. C. Freed, W. Hurni, J. M. Aste-Amezaga, L. Guan, R. Long, L. Huang, V. Harris, D. K. Nawrocki, H. Mach, R. D. Troutman, L. A. Isopi, K. K. Murthy, K. Rice, K. A. Wilson, D. B. Volkin, E. A. Emini, and J. W. Shiver. 2003. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. *J Virol.* **77**:7663-7668.
- 20 5. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression and replication. *Annu. Rev. Microbiol.* **44**:649.
6. Chang, G.-J. J., A. R. Hunt, and B. Davis. 2000. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. *Journal of Virology* **74**:4244-4252.
- 25 7. Chen, H. W., C. H. Pan, M. Y. Liau, R. Jou, C. J. Tsai, H. J. Wu, Y. L. Lin, and M. H. Tao. 1999. Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines. *J. Virol.* **73**:10137-10145.
- 30 8. Chengalvala, M. V., B. M. Bhat, R. A. Bhat, S. K. Dheer, M. D. Lubeck, R. H. Purcell, and K. K. Murthy. 1997. Replication and immunogenicity of Ad7-,

- Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Vaccine 15:335-339.
9. **Flanagan, B., C. R. Pringle, and K. N. Leppard.** 1997. A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. J Gen. Virol. 78 ( Pt 5):991-997.
  10. **Fonseca, B. A., S. Pincus, R. E. Shope, E. Paoletti, and P. W. Mason.** 1994. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 12:279-285.
  11. **Fooks, A. R., D. Jeevarajah, J. Lee, A. Warnes, S. Niewiesk, M. ter, V, J. R. Stephenson, and J. C. Clegg.** 1998. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. J Gen. Virol. 79 ( Pt 5):1027-1031.
  12. **Guirakhoo, F., R. Weltzin, T. J. Chambers, Z. X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath.** 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 74:5477-5485.
  13. **Imler J.L.** 1995. Adenovirus vectors as recombinant viral vaccines. Vaccine 13:1143-1151.
  14. **Jan, L. R., C. S. Yang, L. S. Henchal, H. Sumiyoshi, P. L. Summers, D. R. Dubois, and C. J. Lai.** 1993. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein. Am. J Trop. Med. Hyg. 48:412-423.
  15. **Kaur, R., G. Sachdeva, and S. Vrati.** 2002. Plasmid DNA immunization against Japanese Encephalitis Virus: immunogenicity of membrane-anchored and secretory envelope protein. J. Infect. Dis. 185:1-12.
  16. **Kaur, R. and S. Vrati.** 2003. Development of a recombinant vaccine against Japanese encephalitis. J Neurovirol 9:421-431.
  17. **Kimura-Kiroda, J. and K. Yasui.** 1988. Protection of mice against Japanese encephalitis virus by passive administration of monoclonal antibodies. J. Immunol. 141:3606-3610.
  18. **Konishi, E., S. Pincus, E. Paoletti, R. E. Shope, T. Burrage, and P. W. Mason.** 1992. Mice immunized with a subviral particle containing the Japanese

- encephalitis virus prM/M and E proteins are protected from lethal JEV infection. *Virology* **188**:714-720.
19. **Konishi, E., M. Yamaoka, S. W. Khin, I. Kurane, K. Takada, and P. W. Mason.** 1999. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. *J. Virol.* **73**:5527-5534.
- 10 20. **Konishi, E., M. Yamaoka, Khin-Sane-Win, I. Kurane, and Mason P.W.** 1998. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. *Journal of Virology* **72**:4925-4930.
- 15 21. **Lemiale, F., W. P. Kong, L. M. Akyurek, X. Ling, Y. Huang, B. K. Chakrabarti, M. Eckhaus, and G. J. Nabel.** 2003. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. *J Virol.* **77**:10078-10087.
22. **Lin; B., C. R. Parrish, J. M. Murray, and P. J. Wright.** 1994. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. *Virology* **202**:885-890.
- 20 23. **Livingston, P. G., I. Kurane, C. J. Lai, M. Bray, and F. A. Ennis.** 1994. Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones. *J Virol.* **68**:3283-3288.
- 25 24. **Lubeck, M. D., A. R. Davis, M. Chengalvala, R. J. Natuk, J. E. Morin, K. Molnar-Kimber, B. B. Mason, B. M. Bhat, S. Mizutani, P. P. Hung, and .** 1989. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. *Proc. Natl. Acad. Sci. U. S. A* **86**:6763-6767.
- 30 25. **Mason P.W., S. Pincus, M. J. Fournier, T. L. Mason, R. E. Shope, and E. Paoletti.** 1991. Japanese encephalitis virus-Vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. *Virology* **180**:294-305.
26. **McMinn, P. C.** 1997. The molecular basis of virulence of the encephalitogenic flaviviruses. *J Gen. Virol.* **78** ( Pt 11):2711-2722.

27. **Men, R., M. Bray, and C.-J. Lai.** 1991. Carboxy-terminal truncated dengue virus envelope glycoprotein expressed on the cell surface and secreted intracellularly exhibit increased immunogenicity in mice. *Journal of Virology* **65**:1400-1407.
- 5      28. **Monath, T. P.** 2001. Prospects for development of a vaccine against the West Nile virus. *Ann. N. Y. Acad. Sci.* **951**:1-12.
29. **Monath, T. P.** 2002. Japanese encephalitis vaccines: current vaccines and future prospects. *Curr. Top. Microbiol. Immunol.* **267**:105-138.
- 10     30. **Monath, T. P., K. McCarthy, P. Bedford, C. T. Johnson, R. Nichols, S. Yoksan, R. Marchesani, M. Knauber, K. H. Wells, J. Arroyo, and F. Guirakhoo.** 2002. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. *Vaccine* **20**:1004-1018.
- 15     31. **Monath, T. P., K. Soike, I. Levenbook, Z. X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. D. Barrett, R. E. Shope, M. Ratterree, T. J. Chambers, and F. Guirakhoo.** 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. *Vaccine* **17**:1869-1882.
- 20     32. **Pan, C. H., H. W. Chen, H. W. Huang, and M. H. Tao.** 2001. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. *J Virol.* **75**:11457-11463.
33. **Plesner, A. M. and T. Ronne.** 1997. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. *Vaccine* **15**:1239-1243.
- 25     34. **Putnak, R., R. Feighny, J. Burrous, M. Cochran, C. Hackett, G. Smith, and C. Hoke.** 1991. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. *Am. J Trop. Med. Hyg.* **45**:159-167.
- 30     35. **Raikwar, S. P., P. Malik, O. Singh, and S. Vrati.** 1997. Recombinant adenovirus synthesizing cell surface-anchored beta hCG induces bioneutralizing antibodies in rats. *Gene* **190**:197-202.
36. **Ramakrishna, C., A. Desai, S. K. Shankar, A. Chandramuki, and V. Ravi.** 1999. Oral immunisation of mice with live Japanese encephalitis virus induces a protective immune response. *Vaccine* **17**:3102-3108.

37. **Raviprakash, K., T. J. Kochel, D. Ewing, M. Simmons, I. Phillips, C. G. Hayes, and K. R. Porter.** 2000. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. *Vaccine* **18**:2426-2434.
- 5 38. **Ruff, T. A., D. Eisen, A. Fuller, and R. Kas.** 1991. Adverse reactions to Japanese encephalitis vaccine. *Lancet* **338**:881-882.
39. **Sakaguchi, M., M. Yoshida, W. Kuroda, O. Harayama, Y. Matsunaga, and S. Inouye.** 2000. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. *Vaccine* **15**:121-122.
- 10 40. **Sharpe, S., A. Fooks, J. Lee, K. Hayes, C. Clegg, and M. Cranage.** 2002. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. *Virology* **293**:210-216.
- 15 41. **Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini.** 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. *Nature* **415**:331-335.
- 20 42. **Vos, A., A. Neubert, E. Pommerening, T. Muller, L. Dohner, L. Neubert, and K. Hughes.** 2001. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. *J Gen. Virol.* **82**:2191-2197.
43. **Vrati, S., V. Agarwal, P. Malik, S. A. Wani, and M. Saini.** 1999. Molecular characterization of an Indian isolate of Japanese encephalitis virus that shows an extended lag phase during growth. *J. Gen. Virol.* **80**:1665-1671.

44. **Vrati, S., R. K. Giri, A. Razdan, and P. Malik.** 1999. Complete nucleotide sequence of an Indian strain of Japanese encephalitis virus: sequence comparison with other strains and phylogenetic analysis. *Am. J. Trop. Med. Hyg.* **61**:677-680.
45. **World Health Organization.** 1998. Japanese encephalitis vaccines. *Wkly Epidemiol Rec* **73**:334-344.
- 5
46. **Xiang, Z., Y. Li, G. Gao, J. M. Wilson, and H. C. Ertl.** 2003. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. *J Immunol.* **171**:4287-4293.
47. **Xiang, Z. Q., G. P. Gao, A. Reyes-Sandoval, Y. Li, J. M. Wilson, and H. C. Ertl.** 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. *J Virol.* **77**:10780-10789.
- 10
48. **Xiang, Z. Q., Y. Yang, J. M. Wilson, and H. C. Ertl.** 1996. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. *Virology* **219**:220-227.
- 15
49. **Yoshida, T., K. Okuda, K. Q. Xin, K. Tadokoro, J. Fukushima, S. Toda, E. Hagiwara, K. Hamajima, T. Koshino, and T. Saito.** 2001. Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. *Clin. Exp. Immunol.* **124**:445-452.
- 20
50. **Zhao, J., Y. Lou, J. Pinczewski, N. Malkevitch, K. Aldrich, V. S. Kalyanaraman, D. Venzon, B. Peng, L. J. Patterson, Y. Edghill-Smith, R. Woodward, G. N. Pavlakis, and M. Robert-Guroff.** 2003. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. *Vaccine* **21**:4022-4035.